Loading...
Market
What progress will Poseida's CAR-T therapy pipeline make post-acquisition by December 31, 2025?
2
Resolution / Starting Odds
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Company press releases, clinical trial registries, or industry reports
Story
Roche to Acquire Poseida Therapeutics for $9 Per Share Plus $4 CVR in $1.5 Billion CAR-T Deal
Nov 26, 2024, 06:45 AM
Roche Holding AG has entered into a definitive agreement to acquire California-based Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies, for $9 per share in cash, totaling $1 billion upfront. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the total potential value of the deal to $1.5 billion. This transaction represents a significant premium of approximately 200% over Poseida's recent share price. The acquisition includes Poseida's cell therapy candidates and related platform technologies, which focus on developing off-the-shelf CAR-T therapies for the treatment of autoimmune diseases, hematological malignancies, and solid tumors.
View original story
Similar markets
Above $10 • 25%
$8-$10 • 25%
$6-$8 • 25%
Below $6 • 25%
Full $1.5 billion • 25%
$1.25 - $1.5 billion • 25%
$1 - $1.25 billion • 25%
Below $1 billion • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Major changes • 25%
Minor changes • 25%
No changes • 25%
Discontinues gene therapy • 25%
Yes • 50%
No • 50%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%